Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at Leerink Partnrs from an "underperform" rating to a "market perform" rating.
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $121.00 to $168.00. They now have a "buy" rating on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at SVB Leerink LLC from an "underperform" rating to a "market perform" rating. They now have a $97.00 price target on the stock, up previously from $50.00.
Blueprint Medicines: Rampant Growth Mostly Priced In [Seeking Alpha]